Misplaced Pages

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Annexin Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (February 2015) (Learn how and when to remove this message) The topic of this article may not meet Misplaced Pages's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "Annexin Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (October 2016) (Learn how and when to remove this message) (Learn how and when to remove this message)

Annexin Pharmaceuticals is a Swedish privately held biotech company developing new therapeutic approaches for inflammatory cardiovascular diseases. The concept for the therapy is based on the anti-inflammatory properties of Annexin A5, a body own protective protein that acts simultaneously against several key pathogenic mechanisms of cardiovascular diseases. The company is currently focusing on treatment of peripheral artery disease (PAD).

References

1. Martz, Lauren (May 26, 2014). "Annexin: Attenuating vascular inflammation" (PDF). BioCentury: A18. Retrieved 1 February 2015.
2. "Allabolag.se - Företagsinformation om alla Sveriges bolag".

External links

• www.annexinpharmaceuticals.com

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Pharmaceutical companies of Sweden
• Pharmacology stubs